CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX) today announced positive results from a Phase 1 clinical study evaluating the relative bioavailability of an oral once-daily aligned-release (AR) formulation of SynaviveTM (CRx-102). The pharmacokinetic profiles observed in this study suggest that a once-daily Synavive AR formulation may provide similar exposure and improved tolerability in comparison to the twice-daily (BID) formulation of Synavive used in Phase 2 studies to-date. Synavive was well-tolerated and there were no study drug-related serious adverse events reported. The most commonly reported adverse event was headache, a known side-effect of dipyridamole. The headache rate of 30% for the once-daily Synavive AR formulation was less than the approximately 50% headache rate previously reported with Synavive BID in Phase 2 clinical trials.
